Binimetinib
186517
Phase 1 small_molecule terminated
Quick answer
Binimetinib for ALK Gene Rearrangement is a Phase 1 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).
Program details
- Company
- TAKEDA PHARMACEUTICAL CO LTD
- Indication
- ALK Gene Rearrangement
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- terminated